The Science and Research Papers Backing our Ingredients
Metaboost Compound Plant Extract™(Lemon Verbena + Hibiscus Extract)
"Participants supplemented with Metabolaid demonstrated decreased appetite sensation during several hours after a meal, coinciding with increased satiety, and resulting in less food intake. GLP-1 levels were increased, ghrelin was reduced, and decreases in LDL cholesterol and fat mass were detected."
Morillas-Ruiz, J. M., et al. (2022). Effectiveness of a polyphenolic extract (Lippia citriodora and Hibiscus sabdariffa) on appetite regulation in overweight and obese grade I population: an 8-week randomized, double-blind, cross-over, placebo-controlled trial. European Journal of Nutrition, 61, 1763–1776.
"The combination of hibiscus and lemon verbena extracts has a synergistic effect on AMPK activation, increasing it over six-fold compared to the individual extracts alone. Metabolaid modulates the gut bacteriome to higher relative abundances of Bifidobacterium, Blautia, and Faecalibacterium, and promotes increases in short-chain fatty acid production, particularly butyric acid."
Martínez-Rodríguez, A., et al. (2024). Effects of Metabolaid® supplementation on body composition and metabolic parameters in overweight adults: A double-blind, placebo-controlled, randomized clinical trial. Journal of Applied Sciences, 14(5).
"In clinical studies, two months of Metabolaid supplementation was linked to a 61% higher GLP-1 response vs placebo, GLP-1 levels 55% above baseline, and ghrelin (hunger hormone) suppression for up to 4 hours post-meal. Body weight, fat mass, and waist circumference were significantly reduced in the Metabolaid group."
Caturla, N., et al. (2017). Hibiscus and lemon verbena polyphenols: Assessment for weight management in overweight volunteers. Appetite control and satiety. Free Radical Biology and Medicine, 108, S22.
Biosooth™ L.Acidophilus Probiotics
"Abdominal bloating improved significantly in the probiotic group compared to placebo at 4 weeks (severity score: 4.10 vs 6.17, P=0.009) and 8 weeks (P<0.01). L. acidophilus NCFM and Bifidobacterium lactis Bi-07 twice daily improve symptoms of bloating in patients with functional bowel disorders."
Ringel-Kulka, T., Palsson, O. S., Maier, D., Carroll, I. M., Galanko, J. A., Leyer, G. J., & Ringel, Y. (2011). Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: A double-blind study. Journal of Clinical Gastroenterology, 45(6), 518–525.
"L. acidophilus NCFM was identified as the active probiotic component in reducing visceral sensitivity and bloating in patients with functional abdominal pain. The strain induced colonic mu-opioid receptor (MOR) and CB2 expression, helping modulate pain and discomfort signaling."
Ringel-Kulka, T., Goldsmith, J. R., Carroll, I. M., Barros, S. P., Palsson, O., Jobin, C., & Ringel, Y. (2014). Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain: A randomized clinical study. Alimentary Pharmacology & Therapeutics, 40(2), 200–207.
"Consumption of the 2-strain mixture of L. acidophilus over 8 weeks significantly decreased flatus and composite IBS symptom scores compared with placebo at the end of the trial."
Lyra, A., et al. (2016). A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Food & Nutrition Research, 60(1), 31011.
Korean Rhamnoguard™ L.Rhamnosus Probiotics
“In a randomized, double-blind, placebo-controlled trial, adults with functional constipation tendencies who received RH3201 (1×10¹⁰ CFU/day) for 8 weeks showed significant improvements in bowel movement frequency, abdominal discomfort, and IBS-SSS scores, alongside favorable shifts in fecal microbiome composition and metabolomic profiles.”
Choi, S., et al. (2024). Effect of Lacticaseibacillus rhamnosus IDCC 3201 on gut health and bowel function: A randomized, double-blind, placebo-controlled study. Inha University / Ildong Bioscience. Registered at CRIS (KCT0009026).
“L. rhamnosus IDCC3201 supplementation resulted in significant enhancements in body composition, including lean mass and muscle strength, by modulating the gut microbiome and increasing production of branched-chain amino acids (BCAAs). IDCC3201 also increased Allobaculum genus abundance in gut microbiota.”
Park, S., et al. (2024). Dietary supplementation with Lacticaseibacillus rhamnosus IDCC3201 alleviates sarcopenia by modulating the gut microbiota and metabolites in dexamethasone-induced models. PLOS ONE / PubMed. doi:10.1371/journal.pone.0302032.
“IDCC3201 demonstrated protective effects on motor functions and reduced anxiety levels in a chronic stress mouse model, supporting the gut-brain axis modulation properties of this strain. The strain significantly reduced pro-inflammatory cytokines TNF-α and IL-6 caused by LPS challenge.”
Kim, B., et al. (2023). Protective effects of Lacticaseibacillus rhamnosus IDCC3201 on motor functions and anxiety levels in a chronic stress mouse model. Frontiers in Microbiology. PMC10636227.
White Kidney Bean Extract (Phaseolus vulgaris)
“In a randomized, double-blind, placebo-controlled 12-week trial in 81 participants, Phase 2 white kidney bean extract significantly reduced body weight, fat mass, BMI, waist, hip, and thigh circumference in a dose-dependent manner. Phase 2 is an effective and safe supplement aiding weight and fat loss.”
Jäger, R., et al. (2024). Proprietary alpha-amylase inhibitor formulation from white kidney bean (Phaseolus vulgaris L.) promotes weight and fat loss: A 12-week, double-blind, placebo-controlled, randomized trial. Scientific Reports, 14, 13067. doi:10.1038/s41598-024-63443-8.
“Phase 2 has demonstrated the ability to reduce carbohydrate absorption by up to 66% by inhibiting alpha-amylase. Clinical studies show Phase 2 reduces post-prandial blood glucose spikes by 20–40%, and induces weight loss with doses from 500 to 3000 mg per day in either single or divided doses.”
Barrett, M. L., & Udani, J. K. (2011). A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control. Nutrition Journal, 10(1), 24. doi:10.1186/1475-2891-10-24.
“The Phaseolus vulgaris extract group lost an average of 2.24 kg (0.448 kg/week) compared to 0.29 kg in the placebo group over 35 days (p<0.01). Body fat decreased by 1.53% and subcutaneous fat thickness was significantly reduced at all measurement points. No adverse or side effects were observed.”
Zhao, Y., et al. (2020). Regular intake of white kidney beans extract (Phaseolus vulgaris L.) induces weight loss compared to placebo in obese human subjects. Phytotherapy Research, 34(5), 1182–1191. PMC7063375.
Patented Gold Kiwifruit Powder (Prebiotic) — Livaux™ & Actazin™
“In the functionally constipated group, Faecalibacterium prausnitzii abundance significantly increased from 3.4% to 7.0% following Livaux supplementation, with eight of nine participants showing a net increase. Low F. prausnitzii is associated with IBS, atopy, diabetes, and inflammatory bowel diseases including Crohn's disease.”
Blatchford, P., et al. (2017). Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: A randomised controlled human trial. Journal of Nutritional Science, 6, e52. doi:10.1017/jns.2017.52.
“In a randomized, placebo-controlled, double-blinded study using 600 mg of Actazin, participants experienced clinically significant improvements in stool formation and bowel habits. Unlike other laxative forms, Actazin was safe and well tolerated. The slow-fermenting fibers of Actazin and Livaux produce SCFAs which enhance the absorption of minerals including calcium and magnesium.”
Ansell, J., et al. (2015). Kiwifruit-derived supplements increase stool frequency in healthy adults: A randomised, double-blind, placebo-controlled study. Nutrition Research, 35(5), 401–408.
Patented Chromium Picolinate
“Chromax chromium picolinate significantly reduced hunger levels by 24%, food intake by 25%, and cravings for high-fat foods in adult, non-diabetic, overweight women. Participants receiving chromium picolinate reduced their caloric intake by an average of 365 calories per day between baseline and final (week 8) visit.”
Anton, S. D., et al. (2008). Effects of chromium picolinate on food intake and satiety. Diabetes Technology & Therapeutics, 10(5), 405–412. Conducted at Pennington Biomedical Research Center.
“In a double-blind, multicenter, 8-week study of 113 adults with atypical depression, chromium picolinate (600 mcg/day) produced significantly greater improvements in carbohydrate craving, appetite increase, and increased eating compared to placebo. In the subpopulation with high carbohydrate craving, overall symptom scores improved significantly in the chromium group (65% vs 33% placebo; p < 0.05).”
Davidson, J. R., Abraham, K., Connor, K. M., & McLeod, M. N. (2003). Effectiveness of chromium in atypical depression: A placebo-controlled trial. Biological Psychiatry, 53(3), 261–264. PubMed PMID: 16184071.
“Chromium treatment improved appetite and glucose regulation in various patient populations. A 6-month double-blind placebo-controlled trial of 24 overweight adults with binge eating disorder showed numerically greater reductions in binge frequency and weight in chromium groups, with significantly reduced fasting glucose compared to placebo.”
Brownley, K. A., et al. (2013). A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: Results of the Binge Eating and Chromium (BEACh) study. Journal of Psychosomatic Research, 75(1), 36–42. doi:10.1016/j.jpsychores.2013.04.006.
Ginger Root Extract (Zingiber officinale)
“A daily dose of 2000 mg of ginger is beneficial for reducing inflammation, dyspepsia, and gastrointestinal discomfort. Ginger is renowned in traditional Chinese medicine for stimulating digestive juices, promoting gastric motility, and relieving gastrointestinal discomfort. A systematic review of 24 meta-analyses found consistent evidence for ginger's therapeutic effects on nausea, bowel function, and inflammatory markers.”
Abeysekera, W. K. S. M., et al. (2024). Preventive and therapeutic effects of ginger on bowel disease: A review of clinical trials. Advances in Integrative Medicine. doi:10.1016/j.aimed.2024.00099.
“Ginger extract ameliorates obesity and inflammation via regulating microRNA-21/132 expression and AMPK activation in white adipose tissue. Ginger-fed groups had lower serum and hepatic lipid levels, lower mRNA levels of adipogenic genes, and lower pro-inflammatory cytokines compared to high-fat diet groups.”
Kim, S., Lee, M. S., Jung, S., Son, H. Y., Park, S., Kang, B., Kim, C. T., & Kim, Y. (2018). Ginger extract ameliorates obesity and inflammation via regulating MicroRNA-21/132 expression and AMPK activation in white adipose tissue. Nutrients, 10(11), 1567. doi:10.3390/nu10111567.
“Ginger root extract improved gut health in diabetic rats via improvements in intestinal barrier function, mitochondrial function, and anti-inflammation. GEG supplementation reduced intestinal oxidative stress, improved tight junction proteins, and enhanced pancreatic insulin production.”
Li, J., et al. (2022). Ginger root extract improves GI health in diabetic rats by improving intestinal integrity and mitochondrial function. Nutrients, 14(20), 4384. PMC9611027.
Apple Cider Vinegar (Acetic Acid)
“A 2021 meta-analysis of nine clinical trials published in BMC Complementary Medicine and Therapies found that consuming apple cider vinegar lowered fasting blood glucose and HbA1c in people with type 2 diabetes, and also reduced total cholesterol. Three mechanisms are implicated: slowing gastric emptying, blocking starch breakdown into glucose, and increasing glucose uptake in muscle cells.”
Hadi, A., et al. (2021). The effect of apple cider vinegar on lipid profiles and glycemic parameters: A systematic review and meta-analysis of randomized clinical trials. BMC Complementary Medicine and Therapies, 21(1), 179.
“A 12-week study in Bioscience, Biotechnology, and Biochemistry found that participants who took daily apple cider vinegar supplements lost an average of 4 pounds more than the placebo group, without major dietary changes. A subsequent meta-analysis confirmed that ACV supplementation may be a promising adjunctive strategy for short-term weight management in adults with excess body weight.”
Kondo, T., Kishi, M., Fushimi, T., Ugajin, S., & Kaga, T. (2009). Vinegar intake reduces body weight, body fat mass, and serum triglyceride levels in obese Japanese subjects. Bioscience, Biotechnology, and Biochemistry, 73(8), 1837–1843.
Kombucha Powder (Fermented Tea)
“A controlled clinical study at UC San Diego found that kombucha supplementation significantly altered the composition of the gut microbiome, with the relative abundance of Weizmannia — a kombucha-associated probiotic — overrepresented in consumers at end of intervention. Kombucha modulated gut microbial composition consistent with earlier fermented food studies.”
Ecklu-Mensah, G., et al. (2024). Modulating the human gut microbiome and health markers through kombucha consumption: A controlled clinical study. Scientific Reports, 14, 31789. doi:10.1038/s41598-024-80281-w.
“A systematic review and meta-analysis on fermented dairy products found an association between fermented food consumption and reduced risk of type 2 diabetes. A 2021 human dietary intervention study demonstrated that high fermented food consumption increased microbiome diversity and correlated with improvements in several serum markers of inflammation.”
Wastyk, H. C., et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell, 184(16), 4137–4153. doi:10.1016/j.cell.2021.06.019.
“Kombucha reduced hyperglycemia in type 2 diabetic mice by regulating gut microbiota and its metabolites. Additionally, a randomized placebo-controlled crossover trial found that consuming kombucha with a standard carbohydrate meal reduced glycemic and insulin index responses compared to control beverages.”
Atkinson, F. S., Cohen, M., Lau, K., & Brand-Miller, J. C. (2023). Glycemic index and insulin index after a standard carbohydrate meal consumed with live kombucha: A randomised, placebo-controlled, crossover trial. Frontiers in Nutrition, 10, 1036717. doi:10.3389/fnut.2023.1036717.
NutriSorb+™ Postbiotics (PE0401)
“Taking just 0.2g of Totipro Postbiotic PE0401 daily improved bowel movement, constipation, and other digestive symptoms in clinical study. Totipro has been clinically demonstrated to exhibit antibacterial effects against antibiotic-resistant pathogens including MRSA and ESBL, and to effectively inhibit Helicobacter pylori (H. pylori) growth.”
Glac Biotech Co., Ltd. (2023). Totipro® Postbiotic PE0401: Clinical Evidence Summary. DKSH Discover. Available at: https://www.dkshdiscover.com/en/articles/postbiotics-a-new-era-in-gut-heat/totipro.
“A postbiotic consisting of heat-treated Lactobacilli has a bifidogenic effect in both pure culture and human fermented fecal communities. Supplementation with Lactobacillus LB led to increases in Bifidobacterium spp. and associated increases in acid production — changes considered beneficial as high Bifidobacterium levels are linked to decreased intestinal permeability, inhibition of enteropathogens, and improved insulin sensitivity.”
Warda, A. K., Clooney, A. G., Ryan, F., de Almeida Bettio, P. H., Di Benedetto, G., Ross, R. P., & Hill, C. (2021). A postbiotic consisting of heat-treated Lactobacilli has a bifidogenic effect in pure culture and in human fermented fecal communities. Applied and Environmental Microbiology, 87(8), e02459-20. doi:10.1128/AEM.02459-20.
FloraLean Tri-Probiotics™ Complex
“Synbiotic supplementation increased the abundance of gut bacteria associated with positive health effects, especially Bifidobacterium and Lactobacillus, and increased gut microbiota richness. The consistent change seen across all healthy adult populations after a synbiotic or multi-strain probiotic intervention is an increase in Lactobacillus and/or Bifidobacterium relative abundance.”
Sánchez, M. C., et al. (2020). Effects of synbiotic supplement on human gut microbiota, body composition and weight loss in obesity. Nutrients, 12(7), 1999.
“A randomized, double-blind, placebo-controlled study of a synbiotic containing Lactobacillus and Bifidobacterium strains with short-chain fructooligosaccharides in IBS-D patients showed significant improvements in abdominal discomfort, bowel habit, and overall IBS symptom severity score. Multi-strain formulas targeting both Lactobacillus and Bifidobacterium consistently outperform single-strain interventions in gut symptom relief.”
Skrzydło-Radomańska, B., et al. (2021). The effectiveness of synbiotic preparation containing Lactobacillus and Bifidobacterium probiotic strains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome. Nutrients, 13(7), 2112.
“A systematic review and meta-analysis of clinical trials assessing probiotics, synbiotics, and prebiotics on intestinal permeability markers found that 52 RCTs (3,208 subjects) confirmed probiotic and synbiotic supplementation significantly improves gut barrier integrity. Administered bacteria primarily included Lactobacillus and Bifidobacterium genera.”
Cheng, L. H., et al. (2025). Reinforcing gut integrity: A systematic review and meta-analysis of clinical trials assessing probiotics, synbiotics, and prebiotics on intestinal permeability markers. Pharmacological Research, 200, 107097.
